MDT
97.17
+2.33%↑
VEEV
295.69
+0.08%↑
A
141.95
+2.63%↑
HQY
90.19
-0.24%↓
PHR.US
23.94
+5.88%↑
MDT
97.17
+2.33%↑
VEEV
295.69
+0.08%↑
A
141.95
+2.63%↑
HQY
90.19
-0.24%↓
PHR.US
23.94
+5.88%↑
MDT
97.17
+2.33%↑
VEEV
295.69
+0.08%↑
A
141.95
+2.63%↑
HQY
90.19
-0.24%↓
PHR.US
23.94
+5.88%↑
MDT
97.17
+2.33%↑
VEEV
295.69
+0.08%↑
A
141.95
+2.63%↑
HQY
90.19
-0.24%↓
PHR.US
23.94
+5.88%↑
MDT
97.17
+2.33%↑
VEEV
295.69
+0.08%↑
A
141.95
+2.63%↑
HQY
90.19
-0.24%↓
PHR.US
23.94
+5.88%↑
24h
Current
Min
8.86
Max
9.25
Income | 26M -26M |
---|---|
Sales | 2.1M 2.1M |
Profit margin | -1,213.57 |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +70.45% upside |
Next Earnings | 4 lis 2025 |
---|
Market Cap | 377M |
---|---|
Previous open | 8.13 |
Previous close | 9.02 |
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
8 maj 2025, 19:14 UTC
Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update
DJ
Read
31 gru 2024, 19:15 UTC
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 15 USD 70.45%
High 20 USD
Low 13 USD
Based on 5 Wall Street analysts offering 12 month price targets forVerastem Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
5 ratings
5
Buy
0
Hold
0
Sell
Based on 5 analysts giving stock ratings to Verastem Inc - Dist in the past 3 months.
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$